Hypogonadotropic Hypogonadism - Pipeline Review, H1 2014

Global Markets Direct
April 30, 2014
58 Pages - GMD12072
$2,000.00

Summary

Global Markets Direct’s, ‘Hypogonadotropic Hypogonadism - Pipeline Review, H1 2014’, provides an overview of the Hypogonadotropic Hypogonadism’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Hypogonadotropic Hypogonadism, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hypogonadotropic Hypogonadism and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Hypogonadotropic Hypogonadism
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Hypogonadotropic Hypogonadism and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Hypogonadotropic Hypogonadism products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Hypogonadotropic Hypogonadism pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Hypogonadotropic Hypogonadism
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Hypogonadotropic Hypogonadism pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

'

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Hypogonadotropic Hypogonadism Overview 6
Therapeutics Development 7
Pipeline Products for Hypogonadotropic Hypogonadism - Overview 7
Pipeline Products for Hypogonadotropic Hypogonadism - Comparative Analysis 8
Hypogonadotropic Hypogonadism - Therapeutics under Development by Companies 9
Hypogonadotropic Hypogonadism - Therapeutics under Investigation by Universities/Institutes 11
Hypogonadotropic Hypogonadism - Pipeline Products Glance 12
Late Stage Products 12
Clinical Stage Products 13
Early Stage Products 14
Hypogonadotropic Hypogonadism - Products under Development by Companies 15
Hypogonadotropic Hypogonadism - Products under Investigation by Universities/Institutes 16
Hypogonadotropic Hypogonadism - Companies Involved in Therapeutics Development 17
Merck & Co., Inc. 17
Novartis AG 18
Repros Therapeutics Inc. 19
AlphaMab Co., Ltd 20
Hypogonadotropic Hypogonadism - Therapeutics Assessment 21
Assessment by Monotherapy Products 21
Assessment by Combination Products 22
Assessment by Target 23
Assessment by Mechanism of Action 26
Assessment by Route of Administration 29
Assessment by Molecule Type 31
Drug Profiles 33
enclomiphene - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
corifollitropin alfa - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
BGS-649 - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
kisspeptin 112-121 + [gonadorelin] - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
follitropin alfa biosimilar - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Hypogonadotropic Hypogonadism - Recent Pipeline Updates 40
Hypogonadotropic Hypogonadism - Product Development Milestones 50
Featured News & Press Releases 50
Jan 08, 2014: Repros Initiates Two Head to Head Studies of Androxal Versus the Leading Topical Testosterone Gel 50
Dec 04, 2013: Auxilium Pharmaceuticals Announces Court Grants Upsher-Smith Laboratories Motion For Summary Judgment 50
Nov 25, 2013: FDA Schedules Face to Face Meeting With Repros to Discuss Androxal Efficacy 51
Nov 25, 2013: Repros to Present Data on the Benefits of Testosterone Restoration With Androxal Compared to T Replacement With Gels at 9th Men's Health World Congress 51
Oct 22, 2013: Repros Receives FDA Guidance For Androxal Clinical Program 52
Oct 07, 2013: Repros Announces Three Studies Accepted for Presentation at the Annual Meeting of the Sexual Medicine Society of North America 53
Sep 18, 2013: Repros Provides Additional Information Confirming Success for Study ZA-302 53
Aug 05, 2013: Repros Seeks to Affirm Its Intellectual Property Rights in Androxal 54
Jul 09, 2013: Repros Announces Formation of Androxal Clinical and Commercial Advisory Board 54
May 02, 2013: Repros Reports Second Pivotal Androxal Study Fully Enrolled Ahead Of Schedule 56
Appendix 57
Methodology 57
Coverage 57
Secondary Research 57
Primary Research 57
Expert Panel Validation 57
Contact Us 58
Disclaimer 58

List of Tables
Number of Products under Development for Hypogonadotropic Hypogonadism, H1 2014 7
Number of Products under Development for Hypogonadotropic Hypogonadism - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 10
Number of Products under Investigation by Universities/Institutes, H1 2014 11
Comparative Analysis by Late Stage Development, H1 2014 12
Comparative Analysis by Clinical Stage Development, H1 2014 13
Comparative Analysis by Early Stage Development, H1 2014 14
Products under Development by Companies, H1 2014 15
Products under Investigation by Universities/Institutes, H1 2014 16
Hypogonadotropic Hypogonadism - Pipeline by Merck & Co., Inc., H1 2014 17
Hypogonadotropic Hypogonadism - Pipeline by Novartis AG, H1 2014 18
Hypogonadotropic Hypogonadism - Pipeline by Repros Therapeutics Inc., H1 2014 19
Hypogonadotropic Hypogonadism - Pipeline by AlphaMab Co., Ltd, H1 2014 20
Assessment by Monotherapy Products, H1 2014 21
Assessment by Combination Products, H1 2014 22
Number of Products by Stage and Target, H1 2014 25
Number of Products by Stage and Mechanism of Action, H1 2014 28
Number of Products by Stage and Route of Administration, H1 2014 30
Number of Products by Stage and Molecule Type, H1 2014 32
Hypogonadotropic Hypogonadism Therapeutics - Recent Pipeline Updates, H1 2014 40

List of Figures
Number of Products under Development for Hypogonadotropic Hypogonadism, H1 2014 7
Number of Products under Development for Hypogonadotropic Hypogonadism - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 9
Comparative Analysis by Clinical Stage Development, H1 2014 13
Assessment by Monotherapy Products, H1 2014 21
Number of Products by Top 10 Target, H1 2014 23
Number of Products by Stage and Top 10 Target, H1 2014 24
Number of Products by Top 10 Mechanism of Action, H1 2014 26
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 27
Number of Products by Top 10 Route of Administration, H1 2014 29
Number of Products by Stage and Top 10 Route of Administration, H1 2014 30
Number of Products by Top 10 Molecule Type, H1 2014 31
Number of Products by Stage and Top 10 Molecule Type, H1 2014 32

$2,000.00

Research Assistance

We can help you find
data and analyses
relevant to your needs,
or prepare a custom report.

info@LMRreports.com
+1 212 564 2838
+1 212 564 8133 fax

Custom Research

Need a custom report
tailored to your goals and budget? 

E-mail us your project outline
or call Client Services to speak
with your industry analyst.

info@LMRreports.com
+1 212 564 2838
+1 212 564 8133 fax

Discount Codes

Request Discount Codes
for reports of interest to you.

info@LMRreports.com
+1 212 564 2838
+1 212 564 8133 fax